• 1
    Markovic SN,Erickson LA,Rao RD,Weenig RH,Pockaj BA,Bardia A,Vachon CM,Schild SE,McWilliams RR,Hand JL,Laman SD,Kottschade LA, et al. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc 2007; 82: 36480.
  • 2
    Houghton AN,Polsky D. Focus on melanoma. Cancer Cell 2002; 2: 2758.
  • 3
    Lens MB,Eisen TG. Systemic chemotherapy in the treatment of malignant melanoma. Expert Opin Pharmacother 2003; 4: 220511.
  • 4
    Boon T,Coulie PG,Van den Eynde BJ,van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006; 24: 175208.
  • 5
    Old LJ. Cancer vaccines: an overview. Cancer Immun 2008; 8 ( Suppl 1): 1.
  • 6
    Belardelli F,Ferrantini M,Parmiani G,Schlom J,Garaci E. International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines? Cancer Res 2004; 64: 682730.
  • 7
    Rosenberg SA,Yang JC,Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 90915.
  • 8
    Emens LA,Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 2005; 65: 805964.
  • 9
    Poehlein CH,Ruttinger D,Ma J,Hu HM,Urba WJ,Fox BA. Immunotherapy for melanoma: the good, the bad, and the future. Curr Oncol Rep 2005; 7: 38392.
  • 10
    Taieb J,Chaput N,Schartz N,Roux S,Novault S,Menard C,Ghiringhelli F,Terme M,Carpentier AF,Darrasse-Jeze G,Lemonnier F,Zitvogel L. Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol 2006; 176: 27229.
  • 11
    Apetoh L,Ghiringhelli F,Tesniere A,Obeid M,Ortiz C,Criollo A,Mignot G,Maiuri MC,Ullrich E,Saulnier P,Yang H,Amigorena S, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 10509.
  • 12
    Galluzzi L,Maiuri MC,Vitale I,Zischka H,Castedo M,Zitvogel L,Kroemer G. Cell death modalities: classification and pathophysiological implications. Cell Death Differ 2007; 14: 123743.
  • 13
    van der Most RG,Currie A,Robinson BW,Lake RA. Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity. Cancer Res 2006; 66: 6014.
  • 14
    Bracci L,Moschella F,Sestili P,La Sorsa V,Valentini M,Canini I,Baccarini S,Maccari S,Ramoni C,Belardelli F,Proietti E. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression. B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res 2007; 13: 64453.
  • 15
    Ghiringhelli F,Menard C,Puig PE,Ladoire S,Roux S,Martin F,Solary E,Le Cesne A,Zitvogel L,Chauffert B. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56: 6418.
  • 16
    Proietti E,Greco G,Garrone B,Baccarini S,Mauri C,Venditti M,Carlei D,Belardelli F. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J Clin Invest 1998; 101: 42941.
  • 17
    Dudley ME,Wunderlich JR,Robbins PF,Yang JC,Hwu P,Schwartzentruber DJ,Topalian SL,Sherry R,Restifo NP,Hubicki AM,Robinson MR,Raffeld M, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 8504.
  • 18
    Di Modugno F,Bronzi G,Scanlan MJ,Del Bello D,Cascioli S,Venturo I,Botti C,Nicotra MR,Mottolese M,Natali PG,Santoni A,Jager E, et al. Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response. Int J Cancer 2004; 109: 90918.
  • 19
    Barnstable CJ,Bodmer WF,Brown G,Galfre G,Milstein C,Williams AF,Ziegler A. Production of monoclonal antibodies to group A erythrocytes. HLA and other human cell surface antigens-new tools for genetic analysis. Cell 1978; 14: 920.
  • 20
    Wang E,Miller LD,Ohnmacht GA,Liu ET,Marincola FM. High- fidelity mRNA amplification for gene profiling. Nat Biotechnol 2000; 18: 4579.
  • 21
    Wang E,Ngalame Y,Panelli MC,Nguyen-Jackson H,Deavers M,Mueller P,Hu W,Savary CA,Kobayashi R,Freedman RS,Marincola FM. Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer. Clin Cancer Res 2005; 11: 11322.
  • 22
    Eisen MB,Spellman PT,Brown PO,Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95: 148638.
  • 23
    Ross DT,Scherf U,Eisen MB,Perou CM,Rees C,Spellman P,Iyer V,Jeffrey SS,Van de Rijn M,Waltham M,Pergamenschikov A,Lee JC, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000; 24: 22735.
  • 24
    Romero P,Valmori D,Pittet MJ,Zippelius A,Rimoldi D,Levy F,Dutoit V,Ayyoub M,Rubio-Godoy V,Michielin O,Guillaume P,Batard P, et al. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev 2002; 188: 8196.
  • 25
    Gattinoni L,Powell DJ,Jr,Rosenberg SA,Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006; 6: 38393.
  • 26
    Ghiringhelli F,Larmonier N,Schmitt E,Parcellier A,Cathelin D,Garrido C,Chauffert B,Solary E,Bonnotte B,Martin F. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004; 34: 33644.
  • 27
    Speiser DE,Pittet MJ,Rimoldi D,Guillaume P,Luescher IF,Lienard D,Lejeune F,Cerottini JC,Romero P. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. Semin Cancer Biol 2003; 13: 46172.
  • 28
    Moser B,Wolf M,Walz A,Loetscher P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol 2004; 25: 7584.
  • 29
    Sprent J. Turnover of memory-phenotype CD8+ T cells. Microbes Infect 2003; 5: 22731.
  • 30
    Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006; 6: 595601.
  • 31
    Johnston JA,Bacon CM,Finbloom DS,Rees RC,Kaplan D,Shibuya K,Ortaldo JR,Gupta S,Chen YQ,Giri JD,O'Shea JJ. Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15. Proc Natl Acad Sci USA 1995; 92: 87059.
  • 32
    Gadina M,Sudarshan C,Visconti R,Zhou YJ,Gu H,Neel BG,O'Shea JJ. The docking molecule gab2 is induced by lymphocyte activation and is involved in signaling by interleukin-2 and interleukin-15 but not other common γ chain-using cytokines. J Biol Chem 2000; 275: 2695966.
  • 33
    Santini SM,Lapenta C,Logozzi M,Parlato S,Spada M,Di Pucchio T,Belardelli F. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 2000; 191: 177788.
  • 34
    Moschella F,Bisikirska B,Maffei A,Papadopoulos KP,Skerrett D,Liu Z,Hesdorffer CS,Harris PE. Gene expression profiling and functional activity of human dendritic cells induced with IFN-α-2b: implications for cancer immunotherapy. Clin Cancer Res 2003; 9: 202231.
  • 35
    Panelli MC,Stashower ME,Slade HB,Smith K,Norwood C,Abati A,Fetsch P,Filie A,Walters SA,Astry C,Arico E,Zhao Y, et al. Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol 2007; 8: R8.
  • 36
    Di Pucchio T,Pilla L,Capone I,Ferrantini M,Montefiore E,Urbani F,Patuzzo R,Pennacchioli E,Santinami M,Cova A,Sovena G,Arienti F, et al. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-α results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res 2006; 66: 494351.
  • 37
    Speiser DE,Lienard D,Rufer N,Rubio-Godoy V,Rimoldi D,Lejeune F,Krieg AM,Cerottini JC,Romero P. Rapid and strong human CD8+ T cell responses to vaccination with peptide. IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005; 115: 73946.
  • 38
    Asavaroengchai W,Kotera Y,Mule JJ. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci USA 2002; 99: 9316.
  • 39
    Liu JY,Wu Y,Zhang XS,Yang JL,Li HL,Mao YQ,Wang Y,Cheng X,Li YQ,Xia JC,Masucci M,Zeng YX. Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. Cancer Immunol Immunother 2007; 56: 1597604.